Phase 2a Study of Danicamtiv (MYK-491) in Patients with ChronicHeart Failure with Reduced
Ejection Fraction (HFrEF)
Adriaan A Voors
University of Groningen, Groningen, Netherlands
Presenting author received consultancy fees and/or research support from Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cytokinetics, Merck,
Myokardia, NovoNordisk, Novartis, Roche Diagnostics
This study was funded by MyoKardia, Inc.
Danicamtiv (formerly MYK-491) is an investigational drug
2
HFrEF, heart failure with reduced ejection fraction; LA, left atrial; LV, left ventricular.
Introduction
1. Fernandes S, et al. In: AHA Scientific Sessions. 2019: Abstract 140, p. A15707. Circulation; 2. Tamby J-F, et al. In: ESC Heart Failure Scientific Sessions. 2019: Abstract P1702. HFrEF, heart failure with reduced ejection fraction
AF, atrial fibrillation; BID, twice daily; d, day; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; ULN, upper limit normal.
Attachments
- Original document
- Permalink
Disclaimer
MyoKardia Inc. published this content on 22 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2020 12:06:02 UTC